1-4 of 4
Shaun Decordova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

Free
Robert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, Joaquin Mateo, Jessica S. Brown, Alvaro H. Ingles Garces, Ruth Ruddle, Shaun Decordova, Simone Jueliger, Roberta Ferraldeschi, Oscar Maiques, Victoria Sanz-Moreno, Paul Jones, Stephanie Traub, Gavin Halbert, Sarah Mellor, Karen E. Swales, Florence I. Raynaud, Michelle D. Garrett, Udai Banerji
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4777–4784.
https://doi.org/10.1158/1078-0432.CCR-20-0700
Published: 15 September 2020
View articletitled, First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
Open the PDF for First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Free
Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung-Jue Bang, Jeffrey R. Infante, Li Yan, Johann S. de Bono, Hendrik-Tobias Arkenau
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (19): 5981–5992.
https://doi.org/10.1158/1078-0432.CCR-17-0725
Published: 01 October 2017
View articletitled, A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Free
Sarah Blagden, Aurelius Olmin, Debra Josephs, Chara Stavraka, Andrea Zivi, David J. Pinato, Alan Anthoney, Shaun Decordova, Karen Swales, Ruth Riisnaes, Lorna Pope, Kohei Noguchi, Rie Shiokawa, Michiyasu Inatani, Jenny Prince, Keith Jones, Chris Twelves, James Spicer, Udai Banerji
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5908–5917.
https://doi.org/10.1158/1078-0432.CCR-14-1315
Published: 30 November 2014
View articletitled, First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Open the PDF for First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Free
Timothy A. Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Ivy Fearen, Kyriakos P. Papadopoulos, David Olmos, Richard Baird, Liliana Delgado, Ernestina Tetteh, Robert A. Beckman, Lisa Lupinacci, Ruth Riisnaes, Shaun Decordova, Simon P. Heaton, Karen Swales, Nandita M. deSouza, Martin O. Leach, Michelle D. Garrett, Daniel M. Sullivan, Johann S. de Bono, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5672–5685.
https://doi.org/10.1158/1078-0432.CCR-14-0868
Published: 13 November 2014
View articletitled, Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Open the PDF for Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers in another window
Includes: Supplementary data